[go: up one dir, main page]

CN101687022A8 - Prame衍生的肽以及包括该肽的免疫原组合物 - Google Patents

Prame衍生的肽以及包括该肽的免疫原组合物 Download PDF

Info

Publication number
CN101687022A8
CN101687022A8 CN200880009876.5A CN200880009876A CN101687022A8 CN 101687022 A8 CN101687022 A8 CN 101687022A8 CN 200880009876 A CN200880009876 A CN 200880009876A CN 101687022 A8 CN101687022 A8 CN 101687022A8
Authority
CN
China
Prior art keywords
peptides
prame
immunogenic compositions
derived
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200880009876.5A
Other languages
English (en)
Other versions
CN101687022B (zh
CN101687022A (zh
Inventor
J·凯斯勒
M·格里菲恩
C·J·M·梅里芙
J·W·德里夫霍特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Priority to CN201610596359.9A priority Critical patent/CN106220721B/zh
Publication of CN101687022A publication Critical patent/CN101687022A/zh
Publication of CN101687022A8 publication Critical patent/CN101687022A8/zh
Application granted granted Critical
Publication of CN101687022B publication Critical patent/CN101687022B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种长度小于100个氨基酸的肽，该肽包括源自人PRAME蛋白的氨基酸序列的至少19个连续的氨基酸，其中，所述肽包括源自人PRAME蛋白的氨基酸序列的至少一个II类HLA表位和至少一个I类HLA表位；还涉及所述肽本身以及以组合物的形式用作治疗和/或预防癌症的药物的应用。
CN200880009876.5A 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物 Expired - Fee Related CN101687022B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610596359.9A CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104893 2007-03-26
EP07104893.8 2007-03-26
PCT/NL2008/050171 WO2008118017A2 (en) 2007-03-26 2008-03-26 Prame derived peptides and immunogenic compositions comprising these

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610596359.9A Division CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Publications (3)

Publication Number Publication Date
CN101687022A CN101687022A (zh) 2010-03-31
CN101687022A8 true CN101687022A8 (zh) 2016-08-24
CN101687022B CN101687022B (zh) 2016-09-07

Family

ID=38267662

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201610596359.9A Expired - Fee Related CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物
CN200880009876.5A Expired - Fee Related CN101687022B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201610596359.9A Expired - Fee Related CN106220721B (zh) 2007-03-26 2008-03-26 Prame衍生的肽以及包括该肽的免疫原组合物

Country Status (8)

Country Link
US (3) US8492514B2 (zh)
EP (3) EP3533461A3 (zh)
JP (2) JP5649952B2 (zh)
CN (2) CN106220721B (zh)
AU (1) AU2008230240B2 (zh)
CA (2) CA2996732C (zh)
ES (1) ES2539812T3 (zh)
WO (1) WO2008118017A2 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011062634A2 (en) * 2009-11-18 2011-05-26 Mannkind Corporation Monoclonal antibodies and diagnostic uses thereof
NL2007536C2 (en) 2011-10-05 2013-04-08 Academisch Ziekenhuis Leiden Lumc Adjuvant compound.
JP6366580B2 (ja) * 2012-06-22 2018-08-01 エイチティージー モレキュラー ダイアグノスティクス， インコーポレイテッド メラニン細胞性病変における分子悪性度
WO2014207708A2 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
AU2014298504B2 (en) * 2013-07-30 2018-08-30 Biontech Ag Tumor antigens for determining cancer therapy
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
CN107921127B (zh) * 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 对于prame肽具有特异性的t细胞受体样抗体
EP3112375A1 (en) * 2015-07-03 2017-01-04 Ludwig-Maximilians-Universität München Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris
CN106519019B (zh) * 2015-11-06 2018-07-03 广东香雪精准医疗技术有限公司 识别prame抗原的tcr
CN106831978B (zh) * 2015-12-04 2020-05-26 中国科学院广州生物医药与健康研究院 识别prame抗原的t细胞受体
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
AU2017223267B2 (en) 2016-02-26 2021-07-22 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
CN106699874B (zh) * 2016-03-29 2018-06-05 广东香雪精准医疗技术有限公司 识别prame抗原短肽的t细胞受体
CN107266552B (zh) * 2016-03-30 2022-02-08 香雪生命科学技术（广东）有限公司 源自于prame的肿瘤抗原短肽
US10702598B2 (en) 2016-06-20 2020-07-07 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
CN108203459A (zh) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 源自于prame的肿瘤抗原短肽
CN108203460B (zh) * 2016-12-19 2021-10-08 香雪生命科学技术（广东）有限公司 衍生自肿瘤抗原prame的短肽
CN108264550B (zh) * 2017-01-04 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别源自于prame抗原短肽的tcr
LT3573647T (lt) * 2017-01-27 2023-06-12 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš kiaušidžių ir kitų tipų vėžį
NL2018803B1 (en) 2017-04-27 2018-11-05 Academisch Ziekenhuis Leiden Handelend Onder De Naam Leids Univ Medisch Centrum/ H O D N Lumc Adjuvant compounds
CN108929378B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原的t细胞受体及编码该受体的核酸
GB201709866D0 (en) * 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
CA3068852A1 (en) 2017-07-07 2019-01-10 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
EP3661957A1 (en) * 2017-08-02 2020-06-10 IDP Discovery Pharma, S.L. Anticancer peptides
CN109400696B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr
CN117264963A (zh) * 2017-12-13 2023-12-22 艾诺奥医药品有限公司 靶向prame的癌症疫苗和其用途
CA3223357A1 (en) 2021-07-12 2023-01-19 Brigitte Elisa Anna Burm Improved substance quantification in complex mixtures
WO2024068636A1 (en) 2022-09-27 2024-04-04 Isa Pharmaceuticals B.V. Adjuvanted immunogenic peptides for intradermal administration
EP4601685A1 (en) 2022-10-13 2025-08-20 Isabella Pharma B.V. Modified long peptides suitable for use in immunisation
WO2024149888A1 (en) 2023-01-12 2024-07-18 Isa Pharmaceuticals B.V. Improved lipopeptide quantification
WO2025008085A1 (en) 2023-07-05 2025-01-09 Isa Pharmaceuticals B.V. Immunotherapy for the treatment of prame-expressing cancers

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
CN1212155C (zh) 1998-05-23 2005-07-27 莱顿大学医学中心 用于治疗肿瘤的cd40结合分子和ctl肽
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
EP1118860A1 (en) * 2000-01-21 2001-07-25 Rijksuniversiteit te Leiden Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes
FR2804117B1 (fr) 2000-01-21 2004-08-20 Bio Merieux Procede d'isolement de proteines et/ou d'acides nucleiques, complexes de particules et de proteines et/ou d'acides nucleiques, reactif et applications
AU2001274923A1 (en) * 2000-05-23 2001-12-03 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
AUPQ776100A0 (en) * 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US7202034B2 (en) 2000-12-08 2007-04-10 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2003084467A2 (en) * 2002-04-01 2003-10-16 Euro-Celtique S.A. Epitope constructs comprising antigen presenting cell targeting mechanisms
CA2496888A1 (en) * 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
PT1620456E (pt) * 2003-04-18 2014-04-15 Biotech Synergy Inc Péptidos antigénicos hla-a2 associados a tumor e suas composições
DE602004028468D1 (de) * 2003-06-17 2010-09-16 Mannkind Corp Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
US7340702B2 (en) * 2003-07-23 2008-03-04 Cadence Design Systems, Inc. Method and apparatus for induction proof
WO2006009920A2 (en) 2004-06-17 2006-01-26 Mannkind Corporation Epitope analogs
ES2413079T3 (es) * 2005-06-17 2013-07-15 Mannkind Corporation Métodos y composiciones para desencadenar respuestas inmunitarias multivalentes contra epítopos dominantes y subdominantes expresados en células cancerosas y estroma tumoral
BRPI0611793A2 (pt) * 2005-06-17 2009-01-13 Mannkind Corp anÁlogos de epÍtopo

Also Published As

Publication number Publication date
CA2681132C (en) 2018-05-01
CN101687022B (zh) 2016-09-07
US10450356B2 (en) 2019-10-22
EP3533461A2 (en) 2019-09-04
US20160333065A1 (en) 2016-11-17
ES2539812T3 (es) 2015-07-06
EP2462947B1 (en) 2019-03-13
US20140348862A1 (en) 2014-11-27
JP5985551B2 (ja) 2016-09-06
JP2010522748A (ja) 2010-07-08
AU2008230240A1 (en) 2008-10-02
US9441025B2 (en) 2016-09-13
JP2014240407A (ja) 2014-12-25
CN106220721A (zh) 2016-12-14
US20100120683A1 (en) 2010-05-13
CA2996732C (en) 2020-10-27
WO2008118017A3 (en) 2008-12-31
EP2462947A1 (en) 2012-06-13
AU2008230240B2 (en) 2012-09-13
CN106220721B (zh) 2020-04-07
CA2996732A1 (en) 2008-10-02
EP2125005A2 (en) 2009-12-02
CA2681132A1 (en) 2008-10-02
JP5649952B2 (ja) 2015-01-07
EP2125005B1 (en) 2015-04-08
WO2008118017A2 (en) 2008-10-02
CN101687022A (zh) 2010-03-31
US8492514B2 (en) 2013-07-23
EP3533461A3 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
CN101687022A8 (zh) Prame衍生的肽以及包括该肽的免疫原组合物
UA103751C2 (ru) Иммуногенный пептид для иммунотерапии
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
IL180101A (en) Isolated peptides, peptide complex / mhc class – i, peptide-encoded nucleic acid sequences, immune-containing peptides or nucleic acid sequences and their use in drug preparation
RU2015146614A (ru) Конъюгированная вакцина на основе пептида антигена wt1
ATE461215T1 (de) Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
EP3412304A3 (en) Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
EA201000208A1 (ru) Композиция опухолеассоциированных пептидов и относящаяся к ним противораковая вакцина
EP3219725A3 (en) Dkk1 antibodies and methods of use
MX2009007008A (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EP2383285A3 (en) Peptide Sequences and Compositions
WO2008057463A3 (en) Peptide-based conditioners
EP2380591A3 (en) Vaccine peptide combinations against cat allergy
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
WO2008052173A3 (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
NZ594268A (en) Grass peptides for vaccine
DE60324406D1 (de) Modifizierter faktor viii
MX2011008261A (es) FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.
EP3998276A3 (en) Growth promoting peptides and uses thereof
EP3868778A3 (en) Cdc45l peptides and vaccines including the same
WO2010057275A8 (en) Cyclic peptides and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CI01 Publication of corrected invention patent application

Correction item: Third inventor

Correct: C - J - M - Meilifu

False: Melief Cornelis Johannes Maria

Number: 13

Volume: 26

CI02 Correction of invention patent application

Correction item: Third inventor

Correct: C - J - M - Meilifu

False: Melief Cornelis Johannes Maria

Number: 13

Page: The title page

Volume: 26

ERR Gazette correction
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160907